Novo Nordisk A\/S shares have fallen so much this year that it\u2019s almost as if the frenzy around weight-loss drugs that propelled the Danish pharmaceutical company\u2019s meteoric rise never happened.<\/p>\n
The shares have plunged more than 50% so far in 2025, on track for their worst-ever year, amid disappointing clinical trial results, multiple profit warnings and intense competition in the obesity-drug market. The slump has virtually wiped out several years of stellar gains that came after Novo\u2019s Wegovy drug was approved as a weight-loss treatment in 2021.<\/p>\n
![\"\"](\"https:\/\/www.moneyweb.co.za\/wp-content\/uploads\/2025\/12\/445745053-555x325.jpg\")
<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
It\u2019s a stunning reversal of fortunes for a company that started this year as Europe\u2019s most valuable listed firm. And with the main compound patent for semaglutide \u2014 the key ingredient in Wegovy and Ozempic \u2014 set to expire in 2032 in the US, some investors are worried about where future sales growth will come from.<\/p>\n
ADVERTISEMENT<\/p>\n
CONTINUE READING BELOW<\/p>\n<\/div>\n<\/div>\n
\u201cWhen I look at it right now, organically, their pipeline doesn\u2019t convince me that this situation is manageable,\u201d said Paul Major, a portfolio manager at Bellevue Asset Management. Major, who sold shares in Novo earlier this year, said the stock will probably continue to de-rate until investors see a compelling catalyst to reassure them on Novo\u2019s future growth.<\/p>\n
Novo bulls are hoping that pending approvals of a higher-dose Wegovy shot and an oral version of the drug will turn things around and boost the company\u2019s position against rival Eli Lilly & Co. Novo has sought approval of the stronger injectable version of Wegovy in the US under a priority voucher, which will speed review. For the pill, it\u2019s targeting a launch early next year.<\/p>\n
Explainer: How Novo Nordisk Is Aiming for a Weight-Loss Recovery<\/p>\n
\u201cAssuming approvals and successful launches, both a higher-dose injection and an oral version of Wegovy could work as catalysts for Novo\u2019s share price recovery,\u201d said Gregoire Biollaz, senior investment manager at Pictet Asset Management, which holds Novo shares in its Longevity fund. \u201cThe weight-loss drug that Novo currently has on the market is inducing less weight loss than Lilly \u2014 so Lilly has stronger commercial messaging.\u201d<\/p>\n
Obesity Pill<\/strong><\/p>\n Pricing and availability of the pill will be key. If Novo manages to get its drug to market before Lilly\u2019s version, investors will be scrutinizing how it capitalizes on its first-mover advantage \u2014 something it failed to do with the Wegovy injectable in 2021. The launch will be led by a new chief executive officer and overhauled board under company veteran Lars Rebien Sorensen, who criticized the previous management for being too slow to respond to challenges in the US market.<\/p>\n Mike Doustdar, who took the helm as CEO in August, said last month that Novo has \u201cmore than enough\u201d pills for its target launch. The company has also confirmed it\u2019s in \u201cpreliminary\u201d talks with Hims & Hers Health Inc. to sell the obesity pill on its telehealth site.<\/p>\n \u201cI think they\u2019ve learned their lesson and will be much better and execute better this time around,\u201d said Sebastien Malafosse, a portfolio manager at Edmond de Rothschild Asset Management. As for the company and its share-price slump this year, Malafosse thinks Novo is in a period of transition. \u201cNovo is clearly not dead,\u201d said Malafosse, who holds Novo shares.<\/p>\n A head-to-head trial comparing Novo\u2019s CagriSema drug against Lilly\u2019s Zepbound will be another focus in 2026, while Novo\u2019s initial guidance for the year will also be key for sentiment. Analyst estimates tracked by Bloomberg suggest that sales may drop in 2026, a stark contrast to the 25%-30% growth seen during Novo\u2019s boom years. Clarity on this \u201ccould be the last overhang on the stock,\u201d Pictet\u2019s Biollaz said.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n ADVERTISEMENT:<\/p>\n CONTINUE READING BELOW<\/p>\n<\/div>\n<\/div>\n \u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n The analyst community is still largely positive on Novo, with 17 of the 33 firms tracked by Bloomberg rating the shares a buy as of Wednesday\u2019s market close. For some, like Berenberg\u2019s Kerry Holford, the share-price slump has gone too far and a higher valuation is warranted.<\/p>\n \u201cAt current levels, the shares price in limited pipeline value,\u201d Holford wrote in a note last week. \u201cWe are prepared to pay a higher premium for the pipeline given Novo\u2019s strong R&D returns track record.\u201d<\/p>\n Novo shares trade at around 14 times expected earnings \u2014 about half of their average valuation over the past five years. It\u2019s also more than 10% cheaper than the MSCI World Pharmaceuticals Index.<\/p>\n Novo isn\u2019t the only European obesity stock that has struggled this year, with shares of Zealand Pharma A\/S down almost 30%. Lilly shares, meanwhile, have soared more than 25%.<\/p>\n \u201cThe market has chosen its camp and thinks that only Lilly will benefit from the huge growth in the market, which I think is quite an extreme position,\u201d Edmond de Rothschild\u2019s Malafosse said. \u201cLilly is getting most of the new patients at the moment, but I don\u2019t think it will last.\u201d<\/p>\n \u00a9 2025 Bloomberg<\/p>\n Follow Moneyweb\u2019s in-depth finance and business news on WhatsApp here.<\/em><\/p>\n<\/p><\/div>\n![\"\"](\"https:\/\/www.moneyweb.co.za\/wp-content\/uploads\/2025\/12\/445744647-555x325.jpg\")
<\/p>\n